Chardan Capital Markets Starts Catalyst Biosciences (CBIO) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Catalyst Biosciences (CBIO) & ISU Abxis Announces Completion of Dosing of 1st Patient Cohort in Hemophilia B Clinical Trial
June 14, 2017 8:09 AM EDTCatalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, and ISU Abxis Co Ltd. a commercial-stage biopharmaceutical company and Catalysts collaborator in the development of its Factor IX variant, today announced that ISU Abxis has completed dosing of the first of up to five patient cohorts in a Phase 1/2 proof-of-concept clinical trial in individuals with severe hemophilia B. The Companies plan to have top line data from the trial by the end of 2017.
The clinical trial will include single intravenous and subcutaneous... More
Catalyst Biosciences (CBIO) Announces Presentations on Its Next-Generation Subcutaneous Hemophilia Product Candidates at ISTH Meeting
June 8, 2017 8:05 AM EDTCatalyst Biosciences, Inc. (Nasdaq: CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced that data from two of its product candidates will be presented at the International Society on Thrombosis and Haemostasis (ISTH) Meeting being held in Berlin, Germany from July 8 to 13, 2017.
Catalyst is focused on the prevention of bleeding in individuals with hemophilia through the development of clotting factors that may be injected subcutaneously, rather than intravenously, potentially achieving normal coagulation activity.
Catalyst recently announced that CB 2679d/ISU304, its next-generation Factor IX variant,... More
